The Latest Breaking News from Viking

Our resident chef sizzled dozens of fried eggs and sticky pancakes for this Viking PureGlide Pro Pan review

Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher on Thursday. The clinical-stage biopharmaceutical company seems to be benefitting from wider excitement in the obesity treatment area, as well as recent positive momentum after major clinical trial developments.

Viking Holdings Ltd. (NYSE:VIK) stock rose after reporting third-quarter 2025 results that topped expectations, delivering adjusted EPS of $1.20 versus the $1.19 estimate and revenue of $1.9996 billion, slightly above the $1.992 billion consensus.

Andreas Halvorsen just reminded Wall Street why Viking Global Investors is one of the hedge fund world's most-watched portfolios: he doesn't trim, he swings. Viking's third quarter 13F filing shows a $38.5 billion book that looks like it's been through a full reboot — complete with shock exits, oversized new…

From stainless steel cookware to ceramic pots, I’ve tested and found the best sets

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the SP 500 inching up 0.2% to 6,846.61, while the tech-heavy Nasdaq slipped 0.25% to 23,468.30.

Reztlaff will have a new ride in 2026

Stanley Druckenmiller's Viking Therapeutics Inc (NASDAQ:VKTX) bet is starting to look like a classic Druckenmiller move — quietly bold, impeccably timed, and now technically validated. The billionaire investor's family office took a fresh position in VKTX during the second quarter, buying roughly 549,000 shares at an average price of $25.33.…

Pfizer Inc's (NYSE:PFE) lawsuit. Novo Nordisk A/S' (NYSE:NVO) counterbid. And in the middle of it all — a quiet $45 million position that might turn into Andreas Halvorsen's next masterstroke. After years of fighting from the sidelines of the Ozempic boom, Pfizer is finally throwing punches.